In thyroid carcinomas, inhibition of PI3K or mTOR enhances iodine uptake, raising the possibility of enhanced sensitivity to 131I therapy in cancers in which this pathway is activated (186). The gene discussed is PIK3CB; the disease is thyroid gland carcinoma.